Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn what effects, good and/or bad, Everolimus has on
advanced urothelial cancer.
The goal of this clinical research study is to learn if the study drug Everolimus can shrink
or slow the growth of urothelial cancer. The safety of this drug will also be studied. The
patients physical state, changes in the size of the tumor, and laboratory findings taken
while on-study will help us decide if Everolimus is safe and effective.